{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:06:01Z","timestamp":1759017961318,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.annder.2019.10.031","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T09:19:22Z","timestamp":1577092762000},"page":"279-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["R\u00e9gression de carcinomes basocellulaire et \u00e9pidermo\u00efde cutan\u00e9s sous pembrolizumab"],"prefix":"10.1016","volume":"147","author":[{"given":"L.","family":"Delaitre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Martins-H\u00e9richer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Truchot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Prophette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"B\u00e9n\u00e9ton-Benhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2019.10.031_bib0005","first-page":"9489163","article-title":"A review of the literature of surgical and nonsurgical treatments of invasive squamous cells carcinoma","volume":"2018","author":"Potenza","year":"2018","journal-title":"Bio Med Res Int"},{"key":"10.1016\/j.annder.2019.10.031_bib0010","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/bjd.14642","article-title":"Rescue therapy with anti-programmed cell death protein 1\u00a0inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases","volume":"175","author":"Borradori","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.10.031_bib0015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamadermatol.2015.2705","article-title":"A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1\u00a0inhibitor","volume":"152","author":"Chang","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2019.10.031_bib0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-016-0176-3","article-title":"Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1\u00a0monoclonal antibody REGN2810","volume":"4","author":"Falchook","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annder.2019.10.031_bib0025","doi-asserted-by":"crossref","first-page":"E1663","DOI":"10.3390\/ijms18081663","article-title":"Appearance of new cutaneous superficial basal cell carcinomas during successful nivolumab treatment of refractory metastatic disease: implications for immunotherapy in early versus late disease","volume":"18","author":"Cohen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.annder.2019.10.031_bib0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-017-0228-3","article-title":"Basal cell carcinoma: PD-L1\/PD-1\u00a0checkpoint expression and tumor regression after PD-1\u00a0blockade","volume":"5","author":"Lipson","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annder.2019.10.031_bib0035","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1111\/jdv.14371","article-title":"Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma","volume":"32","author":"Degache","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.10.031_bib0040","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjd.14664","article-title":"Anti-programmed cell death-1\u00a0therapy in nonmelanoma skin cancer","volume":"176","author":"Winkler","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.10.031_bib0045","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.amjmed.2016.12.020","article-title":"Immunotherapy in squamous cell skin carcinoma: a game changer?","volume":"130","author":"Ravulapati","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.annder.2019.10.031_bib0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2017.06.022","article-title":"Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature","volume":"83","author":"Deinlein","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2019.10.031_bib0055","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamadermatol.2016.3884","article-title":"Follow-up on programmed cell death 1\u00a0inhibitor for cutaneous squamous cell carcinoma","volume":"153","author":"Tran","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2019.10.031_bib0060","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jamadermatol.2016.5118","article-title":"Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab","volume":"153","author":"Stevenson","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2019.10.031_bib0065","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3390\/jcm7010010","article-title":"Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and nivolumab","volume":"7","author":"Chen","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.annder.2019.10.031_bib0070","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1684\/ejd.2017.3209","article-title":"Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases","volume":"28","author":"Blum","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2019.10.031_bib0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1\u00a0Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2019.10.031_bib0080","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3\u00a0study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2019.10.031_bib0085","doi-asserted-by":"crossref","first-page":"16037","DOI":"10.1038\/npjgenmed.2016.37","article-title":"Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1\u00a0therapy","volume":"1","author":"Ikeda","year":"2016","journal-title":"NPJ Genomic Med"},{"key":"10.1016\/j.annder.2019.10.031_bib0090","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40425-018-0439-2","article-title":"Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature","volume":"6","author":"Sabbatino","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annder.2019.10.031_bib0095","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jdcr.2018.01.015","article-title":"A case of metastatic basal cell carcinoma treated with continuous PD-1\u00a0inhibitor exposure even after subsequent initiation of radiotherapy and surgery","volume":"4","author":"Cannon","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.annder.2019.10.031_bib0100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000487084","article-title":"Anti-PD-1\u00a0therapy leads to near-complete remission in a patient with metastatic basal cell carcinoma","volume":"41","author":"Fischer","year":"2018","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.annder.2019.10.031_bib0105","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1111\/jdv.15352","article-title":"Anti-PD1\u00a0in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature","volume":"33","author":"Sellah","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.10.031_bib0110","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","article-title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","volume":"17","author":"Sekulic","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annder.2019.10.031_bib0115","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jaad.2018.08.017","article-title":"Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study","volume":"80","author":"Chang","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.10.031_bib0120","doi-asserted-by":"crossref","first-page":"e000236","DOI":"10.1136\/esmoopen-2017-000236","article-title":"Anti-PD-1\/anti-PD-L1\u00a0immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials","volume":"2","author":"Ramos-Esquivel","year":"2017","journal-title":"ESMO Open"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819310324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819310324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:08:40Z","timestamp":1758971320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963819310324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0151963819310324"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2019.10.031","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"R\u00e9gression de carcinomes basocellulaire et \u00e9pidermo\u00efde cutan\u00e9s sous pembrolizumab","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2019.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}